Markets:

Overview

News

Currencies

International

Treasuries

Syndax Pharmaceuticals, Inc. - Common Stock (NQ:SNDX)

21.07 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 29, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Syndax Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Roku To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday ↗

November 18, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 12, 2024

Via Benzinga

Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer ↗

November 12, 2024

Syndax Pharmaceuticals announces positive Phase 2 trial results for revumenib in relapsed/refractory mNPM1 AML, with key milestones expected in 2024 and 2025.

Via Benzinga

Syndax Pharmaceuticals's Earnings: A Preview ↗

November 04, 2024

Via Benzinga

This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

October 24, 2024

Via Benzinga

Syndax Pharmaceuticals: Q4 Earnings Insights ↗

February 27, 2024

Via Benzinga

Earnings Scheduled For February 27, 2024 ↗

February 27, 2024

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.

Via Benzinga

Earnings Preview: Syndax Pharmaceuticals ↗

February 26, 2024

Via Benzinga

Earnings Outlook For Syndax Pharmaceuticals ↗

November 01, 2023

Via Benzinga

FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication ↗

August 15, 2024

The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at least two prior therapies, providing new hope for those with this serious...

Via Benzinga

Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

August 14, 2024

From Incyte and Syndax Pharmaceuticals

Via Business Wire

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

August 01, 2024

From Sagimet Biosciences Inc.

Via GlobeNewswire

Analyst Ratings for Syndax Pharmaceuticals ↗

October 17, 2023

Via Benzinga

3 Biotech Stocks That Could Make Your Summer Unforgettable ↗

July 30, 2024

If you want to do well with biotech stocks, trade the anticipation of news. Here are three stocks to consider.

Via InvestorPlace

Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies

June 17, 2024

EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END

Via FinancialNewsMedia

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

June 10, 2024

From Pyxis Oncology

Via GlobeNewswire

Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies

June 17, 2024

From FN Media Group LLC

Via GlobeNewswire

Why Ooma Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket ↗

May 29, 2024

Via Benzinga

SNDX Stock Earnings: Syndax Pharmaceuticals Beats EPS for Q1 2024 ↗

May 08, 2024

SNDX stock results show that Syndax Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Is The Stock Market Ready To Plunge? The Warning Signs Are Here... ↗

February 21, 2024

Find out how to spot the exhaustion of demand and the bearish analogue you could refer to to anticipate the down move.

Via Talk Markets

What's Going On With Leukemia-Focused Syndax Pharmaceuticals Stock Today? ↗

December 11, 2023

Syndax Pharmaceuticals Inc (NASDAQ: SNDX) shares are trading higher after the company shared data from multiple trials of revumenib in combination with standard-of-care agents in patients with...

Via Benzinga

Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

December 10, 2023

From Incyte and Syndax Pharmaceuticals

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

November 09, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2023 ↗

October 11, 2023

Via Benzinga

What's Going On With Syndax Pharmaceuticals Stock Monday? ↗

October 02, 2023

Syndax Pharmaceuticals Inc (NASDAQ: SNDX) announced topline data from the AUGMENT-101 trial of revumenib in adult and pediatric patients with relapsed/refractory (R/R) KMT2A-rearranged (KMT2Ar) acute...

Via Benzinga

Earnings Scheduled For November 2, 2023 ↗

November 02, 2023

Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

October 05, 2023

On Thursday, 369 companies hit new 52-week lows.

Via Benzinga

Why AERWINS Technologies Shares Are Trading Higher By Around 90%; Here Are 20 Stocks Moving Premarket ↗

October 02, 2023

Gainers AERWINS Technologies Inc. (NASDAQ: AWIN) shares rose 90.2% to $0.2297 in pre-market trading. Aerwins Technologies is considering strategic alternatives for non-core operations including, not...

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

September 29, 2023

Via Benzinga

Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

September 29, 2023

Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share.

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.